Bone Flashcards

1
Q

HORIZON

A

Zolendronic acid

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

FREEDOM trisl

A

Denosumab

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Teriparatide

A

Recombinant parathyroid hormone analogue

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Animal source of Vit D

A

D3 choleclciferol

D2- ergocalciferol plant

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Half life of PTH

A

2 mins

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Effect of PO4 on PTH

A

Increased

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

If you have high PTH levels, why do you have high urine calcium

A

Highinitial filtered load even if PTH serves to increase absorption of calcium

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Site of action of PTH in the kidneys

A

Distal tubules (only 10%)

20% cTAL
The majority in PCT

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Potent activator of PTH2R

A

TIP39

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

PTH receptor which can be activates by PTH but not by PTHrP

A

PTH2 receptor

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Blocks binding of RANKL to RANK (osteoclasts)

A

OSeoprotegerin

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Can not increase urinary cAMP levels in response to PTH show clear renal resistance to PTH

A

Pseudohypoparathyroidism type I

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Induces 1a hydroxylation of Vit D

A

PTH

Hypophosphatemia

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Represses 1a hydroxylation of Vit D

A

Calcium
1,25 OH2 D
FGF23

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Half life of 1,25 dihydrocy vitD

A

6-8 hrs

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Effect of hypomagmesemia on calcium

A

Hypo Mg inhibits PTH hence calcium release hence hypocalcemia

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

Defect in FHH

A

Casr mutation inactivating

Increased ca absorption

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

Decreased urinary cAMP response to PTH

Decreased PO4 response to PTH

A

Pseudohypoparathyroidism 1

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

Pseudohypoparathyroidism 1 aspsxiated with other hormonal resistance

A

Pseudohypoparathyroidism 1a

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

Normal urinary cAMP response to PTH

Decreases PO4 response to PTH

A

Pseduohypoparathyroidism 2

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

Pseudohypoparathyroidism
GNAS1 locus imprinting abnormLity
Not accompanied by any of the clinical features of AHO

A

Pseudohypoparathyroidism 1b

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

Recommended dietary allowance for vitamin D

A

200 IU

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

Recommended dietary allowance for vitamin D in the absence of solar exposure

A

400-600 IU

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

How to differentatiate hypocalcemia of vit D deficiency versus hypoparathyroidism

A

Vit D def has
Phosphatiuria
Pypophosphatemia

25
Short stature Round face foreshortened 4th and other metacarpals Subcutaneous calcifications
Albright hereditary osteodystrophy
26
Vitamin D sufficiency
> 50 nmol /L (20 ng/mL)
27
Rule out fat malabsorption in patients with these levels of vitamin D
<8 ng/dL
28
Effect of anti TB drugs to vitamin D
Increased metabolism
29
When does impaired 1a hydroxylation of Vit D take place
eGFR 30-40/ min
30
EGFR reduce bisphosphonates
< 30 ml/min
31
Bisphosphonate with First dose hypersensitivity
Ibandronic acid
32
Recommended sose or calcitonin
Nasal 200 IU/day | Subcutaneous 100 IU/ day
33
Trial after 6 yrs BMD continued to improce and fracture risk remained low with denosumab
FREEDOM
34
Proteinase that is secreted by osteoclasts and results in bone degradation
Cathepsin k
35
Cathepsin K inhibitor
Odanacatib
36
Improves BMD in spine and hip
Denosumab
37
Why was strontium not approved by FDA
Cardiovascular events
38
AEs include Atypical femus fracture Osteonecrosis of the jaw
Bisphosphonates
39
Anabolic agents
PTH Teriparatide Monoclonal ab to sclerostin
40
Produced by osteocytea and inhibits bone formatuon by blocking Wnt signaling
Sclerostin
41
When is peak bone mass acquir d
Age 10-16 Boys peak 2 yrs later than girls
42
Limut when to take teriparatide | And why
2 yrs | Osteosarcoma in mice
43
Mechanism osteoporosis of Gc
Ucoupling in bone remodeling unit Inhibition of calcium absorption in gut Stimulation of osteoclastogenesis
44
Prevention pf glucocorticoid induced osteoporosis
Bisphosphonates! Zolendronic acid Alendronate Risedronate
45
Hpt jT mutation
Parafibromin / | CDC73 gene
46
Marker of bone formation
Osteocalcin
47
Nadir of calcium post oarathyroidectomy
24-36 hrs
48
Biological actuvity of pth
Amino side | 1-34 aas
49
How many amino acids in PTH
84
50
Cells with PTH receptors
Osteoblast
51
calcium better absorbed
Calcium citrate
52
Form of calcium that requires acidification
Calcium carbonate
53
Highest calcium concent
Calcium carvinate 40% supplemental calcium
54
Picture of pseudohypoparathyroidism
High PTH Low ca High phos ?
55
When to do BMD
Women > /e to 65 | Less than 65 or men with RF tor fracture
56
Give RX in the osteopenic patients with what frax score
HIP fracture >= 3% | Or 20% major osteoporotic fracture
57
Drug holiday
Low risk= drug holiday after 3-5 yrs of treatment Higv risk= after 10 yrs May use teriparatide or raloxifene during drug holiday Reinitiate therapy when BMD decreases
58
Spermarche
13.5
59
% of testosterone from testes
95%